Article Text

PDF
Novel lncRNA T-UCR as a potential downstream driver of the Wnt/β-catenin pathway in hepatobiliary carcinogenesis
  1. Maite G Fernández-Barrena1,2,
  2. Maria J Perugorria2,3,4,
  3. Jesus M Banales2,3,4
  1. 1 Hepatology Program, CIMA of the University of Navarra, Pamplona, Spain
  2. 2 National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain
  3. 3 Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain
  4. 4 IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
  1. Correspondence to Dr Jesus M Banales, Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute—Donostia University Hospital, Paseo del Dr Begiristain s/n, San Sebastián E-20014, Spain; jesus.banales{at}biodonostia.org

Statistics from Altmetric.com

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the most frequent primary liver tumours and their incidence is increasing worldwide. HCC commonly originates from chronic necroinflammation of liver parenchyma that promotes the malignant transformation of proliferating hepatocytes, whereas CCA arises from neoplastic biliary transformation. These types of cancer are frequently diagnosed in advanced stages compromising the limited therapeutic options mainly based on surgery. The molecular and cellular heterogeneity of these tumours, together with their rich tumour microenvironment, contribute to drug resistance and malignant recurrence. This clinical scenario results in poor prognosis.1 ,2

In the last years, intense efforts are being made to ascertain the molecular mechanisms involved in the pathogenesis of both types of cancer in order to find new effective therapeutic options. Understanding liver cancer biology, elucidation of fundamental molecular pathways and determination of genetic and epigenetic abnormalities (ie, DNA methylation, histone modifications and non-coding RNA dysregulation) have strongly emerged as key elements to accomplish this goal. With this vision, in this issue of Gut, Carotenuto et al 3 have identified the ultraconserved long non-coding RNA (lncRNA) uc.158− as a cancer-specific mediator of Wnt/β-catenin pathway in both HCC and CCA. The Wnt/β-catenin signalling pathway is essential in liver pathophysiology regulating cell differentiation, proliferation and survival, among others. Whereas this pathway plays a pivotal role during liver embryogenesis, its impaired and/or excessive activation may promote the development and progression of different cancers, including hepatobiliary tumours. In HCC, ∼50% …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • GI cancer
    Pietro Carotenuto Matteo Fassan Rosantony Pandolfo Andrea Lampis Caterina Vicentini Luciano Cascione Viola Paulus-Hock Luke Boulter Rachel Guest Luca Quagliata Jens Claus Hahne Rachel Ridgway Tam Jamieson Dimitris Athineos Angelo Veronese Rosa Visone Claudio Murgia Giulia Ferrari Vincenza Guzzardo Thomas Ronald Jeffry Evans Martin MacLeod Gui Ji Feng Trevor Dale Massimo Negrini Stuart J Forbes Luigi Terracciano Aldo Scarpa Tushar Patel Nicola Valeri Paul Workman Owen Sansom Chiara Braconi